Compare InMode Ltd (INMD) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Morgan Stanley — how do they compare? InMode Ltd trades at $14.19 (market cap $809.93M), while Morgan Stanley trades at $189.76 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 363.5× InMode Ltd's market cap, and Morgan Stanley pays a 2.45% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Morgan Stanley for 92 Days on average.
| INMD | MS | |
|---|---|---|
Market Cap | $809.93M | $294.39B |
Volume | 365,490 | 5,836,423 |
Sector | Health | Financials |
52-Week High | $16.62 | $228.42 |
52-Week Low | $12.76 | $151.86 |
Typical Hold Time | 28 Days | 92 Days |
Enterprise Value | $313.27M | $660.04B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.14, up 0.93% on the day, with bearish technical signals from moving averages but attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 4.48. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with 76.52% gross margins. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The stock presents value opportunity with solid fundamentals but faces near-term headwinds from cyclical industry softness and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings versus 55% hold, suggesting cautious optimism amid ongoing strategic review of the acquisition proposal.
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
